Normostop Cafeína (Dimenhydrinate, Caffeine)

Dimenhydrinate, the active ingredient in Normostop Cafeína, is a H1 receptor antagonist presented as an oral tablet for oral use. It is combined with caffeine, a central nervous system stimulant, to treat motion‑related nausea, vomiting and general nausea in adults and older children. GNH USA supplies Normostop Cafeína as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dimenhydrinate/Caffeine acts on the vestibular and central pathways that trigger nausea and vomiting. - Motion sickness: reduces vertigo‑induced nausea and vomiting. - Nausea: alleviates acute nausea from various non‑specific causes. - Vomiting: helps control episodes of vomiting associated with vestibular disturbances.

Adverse reactions may occur with any antihistamine‑stimulant combination.

Common Side Effects: - Drowsiness or mild sedation - Dry mouth or throat - Blurred vision - Constipation or stomach discomfort - Increased heart rate or palpitations - Restlessness or mild anxiety

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, rash, swelling) - Cardiac arrhythmias or tachycardia - Seizures - Hallucinations or severe confusion - Persistent vomiting despite therapy

When using Dimenhydrinate/Caffeine, consider the following safety measures. - Pediatric Use: avoid in children under 2 years unless directed by a physician. - Driving and Machinery: do not operate vehicles or heavy equipment until you know how the product affects you. - Alcohol: avoid concurrent consumption as it may enhance drowsiness. - Pre‑existing Conditions: use with caution in patients with glaucoma, urinary retention, or cardiovascular disease. - Pregnancy and Breastfeeding: consult a healthcare professional before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Dimenhydrinate/Caffeine can affect the activity of several other medicines.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system depressants (e.g., benzodiazepines, opioids): enhanced sedation. - Anticholinergic drugs (e.g., atropine, ipratropium): additive anticholinergic effects. - Certain antidepressants (e.g., tricyclics): increased cardiac side effects. - Alcohol: potentiates drowsiness and dizziness.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: caffeine may reduce blood‑pressure‑lowering effect. - Antidiabetic drugs: possible alteration of glucose control. - Other stimulants (e.g., pseudoephedrine): may increase heart rate and anxiety. - Warfarin: caffeine may affect INR stability. - Antiepileptic drugs: potential for reduced seizure threshold.